OTCMKTS:HGENHumanigen Stock Price, Forecast & News

$0.95

-0.15 (-13.64 %)

(As of 04/8/2020 03:46 PM ET)

Add

Compare

Today's Range

$0.92

Now: $0.95▼

$1.19

50-Day Range

$0.33

MA: $0.69▼

$1.35

52-Week Range

$0.30

Now: $0.95▼

$2.04

Volume67,523 shs

Average Volume26,472 shs

Market Capitalization$108.59 million

P/E RatioN/A

Dividend YieldN/A

Beta-1.25

Humanigen, Inc., a biopharmaceutical company, engages in developing its proprietary monoclonal antibodies for immunotherapy and oncology treatments. The company's products include lenzilumab and ifabotuzumab, which are monoclonal antibodies derived from Humaneered platform. Lenzilumab targets granulocyte-macrophage colony-stimulating factor (GM-CSF), and is in development as a potential medicine for chimeric antigen receptor T cell (CAR-T) therapy, as well as a potential treatment for rare hematologic cancers, such as chronic myelomonocytic leukemia (CMML) and juvenile myelomonocytic leukemia (JMML). Ifabotuzumab targets Ephrin type-A receptor 3 (EphA3), and is being explored as a potential treatment for glioblastoma multiforme (GBM) and other cancers, as well as for use in novel CAR-T construct and bispecific antibody platform. The company was formerly known as KaloBios Pharmaceuticals, Inc. and changed its name to Humanigen, Inc. in August 2017. Humanigen, Inc. was founded in 2000 and is based in Burlingame, California.

Beat the Market (BTM) Rank^™

0.0 Analyst's Opinion

Consensus Rating
There is not enough analysis data for Humanigen.

2.5 Community Rank

Outperform Votes
Humanigen has received 117 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Humanigen has received 113 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Humanigen has received 50.87% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Humanigen and other stocks. Vote “Outperform” if you believe HGEN will outperform the S&P 500 over the long term. Vote “Underperform” if you believe HGEN will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Humanigen does not currently pay a dividend.
Dividend Growth
Humanigen does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Humanigen insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 7.10% of the stock of Humanigen is held by insiders.

0.0 Earnings and Valuation

Overall Beat the Market Rank^™

0.50 out of 5 stars

Industry, Sector and Symbol

Stock Exchange OTCMKTS

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

Current SymbolOTCMKTS:HGEN

Previous SymbolNASDAQ:KBIO

CUSIPN/A

CIK1293310

Webhttp://www.humanigen.com/

Phone650-243-3100

Debt

Debt-to-Equity RatioN/A

Current Ratio0.03

Quick Ratio0.03

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual SalesN/A

Price / SalesN/A

Cash FlowN/A

Price / Cash FlowN/A

Book Value($0.13) per share

Price / Book-7.31

Profitability

EPS (Most Recent Fiscal Year)N/A

Net Income$-10,290,000.00

Net MarginsN/A

Return on EquityN/A

Return on Assets-1,199.07%

Miscellaneous

Employees3

Outstanding Shares114,304,000

Market Cap$108.59 million

Next Earnings Date5/1/2020 (Estimated)

OptionableNot Optionable

Receive HGEN News and Ratings via Email

Sign-up to receive the latest news and ratings for HGEN and its competitors with MarketBeat's FREE daily newsletter.

Humanigen (OTCMKTS:HGEN) Frequently Asked Questions

How has Humanigen's stock been impacted by COVID-19 (Coronavirus)?

Humanigen's stock was trading at $0.65 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, HGEN shares have increased by 46.2% and is now trading at $0.95. View which stocks have been mosted impacted by Coronavirus.

When is Humanigen's next earnings date?

Humanigen is scheduled to release its next quarterly earnings announcement on Friday, May 1st 2020. View our earnings forecast for Humanigen.

How were Humanigen's earnings last quarter?

Humanigen Inc (OTCMKTS:HGEN) released its quarterly earnings data on Thursday, November, 10th. The company reported ($0.30) earnings per share for the quarter. View Humanigen's earnings history.

Has Humanigen been receiving favorable news coverage?

News stories about HGEN stock have trended very negative this week, InfoTrie reports. The research firm ranks the sentiment of press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Humanigen earned a media sentiment score of -3.3 on InfoTrie's scale. They also gave headlines about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View the latest news aboutHumanigen.

Who are some of Humanigen's key competitors?

Some companies that are related to Humanigen include RAPT Therapeutics (RAPT), Verastem (VSTM), Urogen Pharma (URGN), Morphic (MORF), Avedro (AVDR), INDIVIOR PLC/S (INVVY), BioSpecifics Technologies (BSTC), G1 Therapeutics (GTHX), BioXcel Therapeutics (BTAI), Kura Oncology (KURA), BioDelivery Sciences International (BDSI), Neoleukin Therapeutics (NLTX), Innate Pharma (IPHYF), AnaptysBio (ANAB) and Atreca (BCEL).

What other stocks do shareholders of Humanigen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Humanigen investors own include Anavex Life Sciences (AVXL), AEterna Zentaris (AEZS), Onconova Therapeutics (ONTX), Tonix Pharmaceuticals (TNXP), Tetraphase Pharmaceuticals (TTPH), VASCO Data Security International (VDSI), ICICI Bank (IBN), Sanchez Energy (SN), Ibio (IBIO) and Achieve Life Sciences (ACHV).

Who are Humanigen's key executives?

Humanigen's management team includes the following people:

Dr. Cameron Durrant M.B.A., M.D., MBA, Chairman & CEO (Age 59)
Mr. J. Gregory Jester, Chief Financial Officer (Age 51)
Mr. Christopher Bowe, Head of Corp. Affairs
Dr. Tarek Sahmoud, Chief Medical Officer

What is Humanigen's stock symbol?

Humanigen trades on the OTCMKTS under the ticker symbol "HGEN."

How do I buy shares of Humanigen?

Shares of HGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Humanigen's stock price today?

One share of HGEN stock can currently be purchased for approximately $0.95.

How big of a company is Humanigen?

Humanigen has a market capitalization of $108.59 million. Humanigen employs 3 workers across the globe. View additional information about Humanigen.

What is Humanigen's official website?

The official website for Humanigen is http://www.humanigen.com/.

How can I contact Humanigen?

Humanigen's mailing address is 533 Airport Boulevard Ste. 400, Burlingame CA, 94005. The company can be reached via phone at 650-243-3100 or via email at [email protected]

This page was last updated on 4/8/2020 by MarketBeat.com Staff